SARS-CoV-2 Helicase Targeted Library

Summary of the technology

The offer SARS-CoV-2 Helicase (NSP13) Targeted Library, which contain 1170 compounds with predicted activity against this vital protein. The overall procedure included accurate flexible docking of Drug-like Green Collection into helicase active site.

Otava Research Institute

Details of the Technology Offer

We offer a target library of SARS-CoV-2 Helicase (NSP13), which contains 1170 compounds with predicted activity on helicase SARS-CoV-2 (non-structural protein 13, NSP13), which is important for coronavirus replication. It separates double-stranded RNA (dsRNA). The identification of small molecules for which the replication apparatus is a target has shown the highest potential for the detection of antiviral drugs.

The library was developed based on virtual screening receptors using a homologous model of SARS-CoV-2 NSP13. Final selection of compounds was performed based on key structural determinants of the enzymatic active site for ligand binding, scoring, and intermolecular hydrogen bonds with key amino acid residues of the active site.

Related Keywords

  • Biological Sciences
  • Medicine, Human Health
  • Biostatistics, Epidemiology
  • Infectious Diseases
  • Applications for Health
  • Human vaccines
  • Genetic Engineering / Molecular Biology
  • Covid-19
  • Medical Health related
  • Diagnostic
  • Diagnostic services
  • Medical/health
  • coronavirus
  • sars-cov-2
  • compounds

About Otava Research Institute

Otava Institute is a global provider of one-stop integrated research solutions for business and life science. Our team includes chemists, biologists, physicists whose combined efforts contribute to the complex contract research projects for pharmaceutical, agro, cosmetic and material science industries.We are dedicated to providing clients with outstanding service in these key areas and will continue to push boundaries to remain an industry front-runner. Each day we expand our core competencies delivering of new technologies to meet all the customer’s needs.

Our location in Toronto Ontario, Canada provides our clients with the added advantage of North American IP rules and regulations and secure communication and logistics. Our Ukraine – based R&D facilities represented with the Ukrainian Laboratories, that is cooperating with leading Ukrainian research institutions and carries out research work in the format of outsourcing.

We work as a preferred partner to many of the world’s top 10 pharma firms, and hundreds of other companies, providing support with creative solutions for complex technical compound issues. Our scientific knowledge, combined with our research and manufacturing capability, enables us to support chemical processing and production without ever compromising on quality.

Our experience, dedication, and commitment to quality make us an ideal partner for discovery stage research.

Nadiia Kachaput

Never miss an update from Nadiia Kachaput

Create your free account to connect with Nadiia Kachaput and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Nadiia

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support